ALPS Medical Breakthroughs ETF
SBIO
66 hedge funds and large institutions have $74.8M invested in ALPS Medical Breakthroughs ETF in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 21 increasing their positions, 14 reducing their positions, and 13 closing their positions.
203% more call options, than puts
Call options by funds: $1.57M | Put options by funds: $519K
50% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 14
1.81% more ownership
Funds ownership: 30.88% → 32.69% (+1.8%)
5% less capital invested
Capital invested by funds: $79M → $74.8M (-$4.18M)
6% less funds holding
Funds holding: 70 → 66 (-4)
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.91M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.52M |
| 3 |
Morgan Stanley
New York
|
+$644K |
| 4 |
FTUS
Flow Traders U.S.
New York
|
+$583K |
| 5 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
+$417K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WIA
Wealthstreet Investment Advisors
Dallas,
Texas
|
-$1.64M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.56M |
| 3 |
FEM
Fulcrum Equity Management
Plano,
Texas
|
-$1.24M |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$749K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$548K |
SBIO Hedge Fund Activity: Q2 2021 in Review
66 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in ALPS Medical Breakthroughs ETF (SBIO) for Q2 2021, worth a combined $74.8M — down 5.3% from $79M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of SBIO and 9 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 21 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $1.91M. The largest seller was Wealthstreet Investment Advisors, exiting entirely with an estimated $1.64M sold.
- 66 institutional investors held ALPS Medical Breakthroughs ETF (SBIO) as of Q2 2021, down from 70 in Q1 2021.
- Funds reported $74.8M of ALPS Medical Breakthroughs ETF stock for Q2 2021, down 5.3% quarter-over-quarter.
- 9 funds opened new ALPS Medical Breakthroughs ETF positions in Q2 2021 and 13 closed out, a net change of -4 holders.
- The largest ALPS Medical Breakthroughs ETF buyer in Q2 2021 was Tower Research Capital (TRC), an estimated $1.91M added.
- The largest ALPS Medical Breakthroughs ETF seller in Q2 2021 was Wealthstreet Investment Advisors, an estimated $1.64M sold.
Based on aggregated 13F filings for Q2 2021.